Author： Jonathan D. Putnam
Publisher： Adis International
ISSN： 1175-2203
Source： American Journal of PharmacoGenomics, Vol.4, Iss.5, 2004-01, pp. : 277-292
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Regulatory Plans for Risks, Benefits, and Costs
By Carr C.J.
Regulatory Toxicology and Pharmacology, Vol. 23, Iss. 3, 1996-06 ,pp. :
Access to resources
Recommend
Costs and Benefits of Direct-to-Consumer Advertising: The Case of Depression
PharmacoEconomics, Vol. 25, Iss. 6, 2007-01 ,pp. :
Indirect costs and benefits of adjuvant trastuzumab evaluated
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 535, 2007-01 ,pp. :
Fulvestrant: benefits at acceptable costs in advanced breast cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 571, 2009-01 ,pp. :